A Study of Oral E1018 in Healthy Adult Participants

NCT06854042 | Recruiting Phase 1 FDA Drug

• 2 other identifiers: E1018-G000-001CDMRPPR210253-A
• Study Type: interventional
• Target: 32
• Locations: 1 country
• Sites: 1

Brief Summary

The primary purpose of the study is to evaluate the safety and tolerability of single ascending oral doses of E1018 in healthy adult participants and to evaluate the pharmacokinetics (PK) of E1018 in plasma and urine after single oral dose administration.

Conditions

Malaria; Healthy Participants

Keywords

E1018

Outcome Measures

Primary Outcomes (14)

• Number of Participants With Dose-limiting Events

  Up to Day 20

• Number of Participants With Adverse Events (Serious and Non-serious)

  Up to Day 20

• Number of Participants With Clinically Significant Laboratory Test Results

  Up to Day 20

• Number of Participants With Clinically Significant Vital Signs Values

  Up to Day 20

• Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Results

  Up to Day 20

• AUC(0-t): Area Under the Concentration-time Curve From Zero Time to Time of Last Quantifiable Concentration for E1018

  Up to Day 20

• AUC(0-inf): Area Under the Concentration-time Curve From Zero Time Extrapolated to Infinite Time for E1018

  Up to Day 20

• Cmax: Maximum Observed Concentration for E1018

  Up to Day 20

• Tmax: Time at Which the Highest Drug Concentration Occurs for E1018

  Up to Day 20

• t½: Terminal Elimination Phase Half-life for E1018

  Up to Day 20

• CL/F: Apparent Total Clearance Following Oral Administration for E1018

  Up to Day 20

• Vz/F: Apparent Volume of Distribution at Terminal Phase for E1018

  Up to Day 20

• Ae: Cumulative Amount of E1018 Excreted in the Urine

  Up to Day 6

• Fe: Percent (%) of Administered E1018 Dose Excreted in Urine

  Up to Day 6

Study Arms (4)

Cohort 1: E1018 or Placebo

EXPERIMENTAL

Drug: E1018; Drug: Placebo

Cohort 2: E1018 or Placebo

EXPERIMENTAL

Drug: E1018; Drug: Placebo

Cohort 3: E1018 or Placebo

EXPERIMENTAL

Drug: E1018; Drug: Placebo

Cohort 4: E1018 or Placebo

EXPERIMENTAL

Drug: E1018; Drug: Placebo

Interventions

E1018 DRUG

Specified dose on specified days.

Cohort 1: E1018 or Placebo; Cohort 2: E1018 or Placebo; Cohort 3: E1018 or Placebo; Cohort 4: E1018 or Placebo

Placebo DRUG

E1018 matching placebo on specified days.

Cohort 1: E1018 or Placebo; Cohort 2: E1018 or Placebo; Cohort 3: E1018 or Placebo; Cohort 4: E1018 or Placebo

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Nonsmoking/vaping, male or female, age greater than or equal to (\>=) 18 years to less than or equal (\<=) 55 years old at the time of informed consent. To be considered nonsmokers, participant must have discontinued smoking/vaping for at least 4 weeks before dosing.
• Body Mass Index (BMI) \>=18 and less than (\<) 30 kilogram per square meter (kg/m\^2) at Screening.

You may not qualify if:

• Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin \[β-hCG\] (or human chorionic gonadotropin \[hCG\]) test with a minimum sensitivity of 25 international units per liter (IU/L) or equivalent units of β-hCG \[or hCG\]). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the dose of study drug.
• Females of childbearing potential. All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (that is, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing).
• Males who have not had a successful vasectomy (confirmed azoospermia) if their female partners are of childbearing potential and are not willing to use a highly effective contraceptive method, as described below, throughout the study period and for 28 days after study drug discontinuation. If the female partner is pregnant, then males who do not agree to use latex or synthetic condoms throughout the study period and for 28 days after study drug discontinuation. No sperm donation is allowed during the study period and for 28 days after study drug discontinuation. The duration may be expanded further based on the half-life of the study drug calculated in this study.
• A highly effective method of contraception includes any of the following:
• total abstinence (if it is their preferred and usual lifestyle)
• an intrauterine device or intrauterine hormone-releasing system
• a contraceptive implant
• an oral contraceptive (the participant's partner must have been on a stable dose of the same oral contraceptive product for at least 28 days before dosing and must agree to stay on the same dose of oral contraceptive throughout the study and for 28 days after study drug discontinuation). It is permissible that if a highly effective method of contraception is not appropriate or acceptable to the participant's partner, then the participant must agree to use a medically acceptable method of contraception, that is, double-barrier methods of contraception such as latex or synthetic condom plus diaphragm or cervical/vault cap with spermicide. The duration of contraception period may be extended based on the half-life of the study drug calculated in this study.
• Clinically significant illness that requires medical treatment within 8 weeks or a clinically significant infection that requires medical treatment within 4 weeks of dosing.
• Presence of concurrent febrile illness(es) at Screening or Baseline.
• Any history of surgery that may affect PK profiles of E1018 (example, hepatectomy, nephrectomy, digestive organ resection) or participants who have a congenital abnormality in metabolism at Screening.
• Any clinically abnormal symptom or organ impairment found by medical history at Screening, and physical examinations, vital signs, ECG finding, or laboratory test results that require medical treatment at Screening or Baseline.
• Left bundle branch block.
• History of myocardial infarction, active ischemic heart disease, or clinically significant or uncontrolled arrhythmia.
• Known history of clinically significant drug allergy at Screening.

Sponsors & Collaborators

• Eisai Inc.: lead

Study Sites (1)

PPD Development, LP

Austin, Texas, 78744, United States

RECRUITING

MeSH Terms

Conditions

Malaria

Condition Hierarchy (Ancestors)

Protozoan Infections; Parasitic Diseases; Infections; Mosquito-Borne Diseases; Vector Borne Diseases

Central Study Contacts

Eisai Medical Information

CONTACT

+1-888-274-2378; esi_medinfo@eisai.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 25, 2025
• First Posted: March 3, 2025
• Study Start: February 26, 2025
• Primary Completion: December 23, 2025
• Study Completion: December 23, 2025
• Last Updated: September 24, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will share

Locations

US (1)